The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | Strategies to prevent resistance in CLL
Sigrid Skånland, PhD, Oslo University Hospital, Oslo, Norway, briefly summarizes methods to prevent resistance to targeted therapies in chronic lymphocytic leukemia (CLL). Dr Skånland draws focus on one strategy, which is to target several pathways by combining different agents, such as venetoclax and ibrutinib. Dr Skånland concludes by mentioning the possibility of using fixed duration therapy in treatment, and the benefits of this method of treatment in cases of relapsed disease. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
